Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum

Size: px
Start display at page:

Download "Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum"

Transcription

1 Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities Johnson & Johnson Pharmaceutical R&D, L.L.C.

2 Our Industry Is Being Transformed Spiraling R&D costs coupled with decreased productivity Ever increasing regulatory requirements Reimbursement driven by medical and economic outcomes Expectation of personalized medicine Proliferation and redistribution of healthcare outcomes information 2

3 Productivity of the Pharmaceutical Industry Sources: FDA/CDER, PhRMA, PricewaterhouseCoopers Note: R&D spending from non-phrma companies not available Drugs Approved R&D Expenditures Drug Approvals R&D Spending (US$ Billions)

4 Pharmaceutical R&D Is a Long Process Identify molecular target Animal Testing Demonstrate efficacy Demonstrate safety and efficacy Basic Research Drug Discovery Pre- Clinical I IIa IIb III FDA Review Synthesize drug candidate Tolerability in humans Identify appropriate dose Apply for marketing approval Years Developing a new drug is a lengthy process Product cycle times are extremely long The 20-year limit on patent protection means there is a limited number of years during which a marketed product can generate an attractive ROI The cost of putting a new drug on the market is $0.8 to $1.3 bn 1 1 Adams C, Brantner V (2006). "Estimating the cost of new drug development: is it really 802 million dollars?". Health Aff 25 (2):

5 Pharmaceutical R&D Is High Risk Cumulative Probability of Success through Key Stagegates 1 Discovery 2 Pre- Clinical I IIa IIb III FDA Review Years Developing a new drug is a risky process When a new drug discovery program is initiated the overall probability of launching a new product is 1.5% 10,000 to 30,000 compounds must be synthesized for every one that reaches the market 1 CMR benchmarks used to calculate risk-adjusted values at various stages 2 Internal estimate of 30% PoS 5

6 R&D Risk Profile Probability of Success by Stagegate % of R&D investment is made in advancing products through Ph IIa Until clinical proof of concept is demonstrated, the probability of success is low Drug Discovery 2 Pre- Clinical I IIa Years IIb III FDA Review 13 1 CMR benchmarks used to calculate risk-adjusted values at various stages 2 Internal estimate of 30% PoS 6

7 Pharmaceutical R&D Current State R&D productivity is decreasing and is not sufficient to drive future growth of the industry Industry consolidation is leading to fewer Large Pharma R&D organizations and the remaining R&D organizations are shedding infrastructure Increasingly, venture capital backed biotech organizations are the source of new products but the traditional venture capital model of creating, funding, and monetizing biotech companies is faltering Large Pharma wants to acquire products, not companies Building fully integrated Biotech companies is not a capital efficient way of generating new products, making product acquisition by Large Pharma prohibitively expensive There is insufficient funding for innovative early-stage product opportunities emerging from academia 7

8 Our Ecosystem Is Interdependent and Fragile Biotech Venture Capital Pharma CRO s Academia Image from the Huffington Post 8

9 Improving R&D Productivity Without a new R&D business model, our industry will not supply an adequate number of innovative new products to drive growth and increase shareholder value Pharmaceutical R&D has become far to costly and complex for any individual company to sustain its business by operating under our traditional model of vertical integration Applying the principles of Open Innovation to align the incentives of all constituents of the ecosystem is essential to creating a new, capital efficient and productive model of pharmaceutical R&D 9

10 The Open Innovation Mindset 1 Closed Innovation We must discover, develop, manufacture and distribute innovations ourselves in a vertically integrated model The requisite expertise in R&D must exist inside of our company If we invent and fund everything internally we will win We must control and conceal our innovation processes, technologies and tools, so that our competitors don't profit from our ideas Open Innovation Enormous value can be unlocked from external R&D and innovation networks Pharmaceutical R&D has become far too complex for us to employ all the expertise needed Creating a better business model for partnered innovation can trump internal invention We will profit from others' use of our innovations and knowledge, and we will leverage others' IP whenever it advances our own business model 1 Adapted from Open Innovation, by Henry Chesbrough Harvard Business School Press,

11 Vertical Integration of Large Pharma Is it Time to Disintegrate? Vertical Integration A characteristic of industries in which firms attempt to own and control all aspects of making, selling, and delivering the product or service that constitutes their core business Examples: Ma Bell, Oil, Steel, Large Pharma Vertical Disintegration A characteristic of industries in which there is an advantage for companies to access from independent suppliers some or all of the materials, intellectual capital, and/or human resources that are essential to delivering the finished product or service that constitutes their core business Examples: Semiconductors, Automobiles, Electronics, Movies 11

12 Vertical Integration of Large Pharma Is it Time to Disintegrate? Core Business Delivering Cost Effective Outcomes Core Functions Research & Early Development Late Development Supply Chain Stakeholder Relations Marketing approval Pricing Reimbursement Policy Sales & Marketing Administration (Legal, Finance, etc.) Support Functions Human Resources Procurement Information Technology Infrastructure (e.g., Engineering, Maintenance, etc.) 12

13 Research & Early Development Disintegration as an Opportunity Research and Early Development Late Development Basic Research Drug Discovery Pre- Clinical I IIa IIb III FDA Review PoS Inflection Point Years Large pharma no longer leads in the area of research and early development Innovation in this stage of the pharmaceutical R&D cycle is spread among thousands of Biotechs and academic laboratories Elements of the research and early development process are becoming commodities 13

14 J&J s External Innovation Initiative By working with experts at other companies, universities, and research institutes, we tap a wider range of expertise, capabilities, and resources. 1 Aggressively pursue licensing activities at all stages of drug development Initiate extensive in-depth collaborations with academia, Biotech companies and CRO s Create new business models for research & early development: the Open Platform 1 Paul Stoffels, Chairman of Pharmaceutical R&D, Johnson & Johnson, Boston Globe, February 2,

15 Open Platform A New Model for R&D Networked Partnering In partnership with external innovators and investors, build and manage an external portfolio of early-stage product opportunities Employ the principles of Open Innovation to identify and advance early-stage innovative product opportunities Link these opportunities with external management expertise and capital Apply internal expertise, capabilities and alliance networks to facilitate the success of our partners Institute innovative financial risk-sharing strategies with external investors to support the development of products Retain options to acquire these opportunities under financial terms that are attractive to both Pharma and its partners 15

16 The Open Platform Concept Basic Research Drug Discovery Pre- Clinical I IIa IIb III FDA Review Academia Pharma Provides: Funding Guidance Expertise Commercialization path Venture Backed External R&D Entity Venture Capital Provides: Capital Management R&D expertise Pharma Provides: Projects R&D expertise R&D infrastructure CRO networks Pharma Pharma Provides: Licensing partner Late development Worldwide commercialization 16

17 Open Platform A New Model for R&D Example of Networked Partnering VCs provide capital, funding syndicate and management team VCs Acme DevCo Pharma Pharma provides projects, guidance, expertise and CRO network Acme Management Team CROs CROs provide virtual, flexible R&D organization Project A Project B Project C Project D Project E Project F Project G Project Project Managers As Needed Total of Projects Entering at 2-3/Year Management team runs multiple projects to exit or termination NuCo or Licensing NuCo or Licensing Exit at end of PhIIa / PoC NuCo or Licensing Exit to Pharma partner, other Pharma or form NuCo

18 Benefits Stakeholders Large Pharma Expand pipeline with an external portfolio of product opportunities Leverage existing infrastructure and expertise Minimize fixed costs and infrastructure while maximizing flexibility Venture Capital Opportunity to invest in market scarcity Assets monetized at an early stage of the R&D process to yield attractive returns with a mid-term horizon Capital investment reduced by accessing Pharma infrastructure and expertise Academia Progress opportunities that would otherwise stagnate Access to external funding vehicles Attractive financial incentives for innovators and universities Contract Research Organizations Expand business Opportunity to risk share

19 Key Learnings Open Innovation must be driven from the top Do not underestimate the organization s capacity to mount an immune response The fear that competitors will profit from Open Innovation can outweigh the promise it holds for your organization Run pilot programs outside of the traditional organizational structure On occasion, ships must be burned to break through entrenched behaviors business practices Do not assume that all external constituents in your industry share your vision 19

Transforming relationships Unleashing innovation

Transforming relationships Unleashing innovation Transforming relationships Unleashing innovation Translating Discoveries Into Products A model for innovation driven economic growth Barbara Handelin, PhD 1 The Innovation Gap Economic Opportunity Industries

More information

Biomedical Accelerator Fund. Office of Technology Development Harvard University

Biomedical Accelerator Fund. Office of Technology Development Harvard University Biomedical Accelerator Fund Office of Technology Development Harvard University Curtis Keith, Chief Scientific Officer May 21, 2012 Mission of Harvard s Office 2 Organizational Structure of Harvard OTD

More information

Trends in IP strategy for young companies viewed from a larger company

Trends in IP strategy for young companies viewed from a larger company Trends in IP strategy for young companies viewed from a larger company Dr David Deperthes Vice President, BD&L, Debiopharm Int. CEO, Debiopharm Diagnostics Agenda General Information on Intellectual Property

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened

More information

Trends in Innovation in Middle Income Countries: The Case of Biotechnology

Trends in Innovation in Middle Income Countries: The Case of Biotechnology Trends in Innovation in Middle Income Countries: The Case of Biotechnology Joseph Damond, Senior Vice President, International Affairs, Biotechnology Industry Organization INNOVATION AND ACCESS TO MEDICAL

More information

The road to positive R&D returns

The road to positive R&D returns 1 F E B R U A R Y 2 0 1 0 p h a r m a c e u t i c a l s & m e d i c a l p r o d u c t s p r a c t i c e The road to positive R&D returns Scientific innovation is not the only route to higher R&D productivity.

More information

An Introduction to Valuations

An Introduction to Valuations An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your

More information

Investing in Invention TM

Investing in Invention TM To Promote the Progress of Useful Arts Investing in Invention TM Peter N. Detkin Founder, Vice Chairman, Intellectual Ventures 1 A THRIVING MARKETPLACE FOR IDEAS Current market undervalues invention and

More information

The Future of Consumer Health Care

The Future of Consumer Health Care The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More

More information

Toward Acceleration of Open Innovation

Toward Acceleration of Open Innovation Toward Acceleration of Open Innovation ーThe Role of Industrial-Academic- Government-Collaborationー Masafumi Nogimori Representative Director and Chairman Astellas Pharm Inc. International Symposium New

More information

Emerging Business Accelerator (EBA) Image Area. Global Innovation Ecosystem. Ajoy Mallik. 2012, Cognizant

Emerging Business Accelerator (EBA) Image Area. Global Innovation Ecosystem. Ajoy Mallik. 2012, Cognizant Emerging Business Accelerator (EBA) Global Innovation Ecosystem Image Area Ajoy Mallik 2012, Cognizant Agenda Introduction to Cognizant Why Innovation Ecosystem? Emerging Business Accelerator (EBA) Global

More information

TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials

TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials Pharmaceutical leader deploys TIBCO Spotfire enterprise analytics platform across its drug discovery organization

More information

Risk & Reward in de Venture Capital wereld

Risk & Reward in de Venture Capital wereld Risk & Reward in de Venture Capital wereld Risk & Reward seminar voor de biotech-, farma en life sciences industrie 24 maart 2011 Hermitage Amsterdam Dr. John de Koning Partner Venture Capital Introduction

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

An Exclusive Interview with Dr Jan-Anders Karlsson

An Exclusive Interview with Dr Jan-Anders Karlsson Dr Jan-Anders Karlsson took over the helm as the CEO of S*BIO from January 2005. He has extensive experience in the pharmaceutical industry, with many proven successes in the drug discovery area. Dr Karlsson

More information

Key Findings. Use this report to... The Top 10 Contract Research Organizations

Key Findings. Use this report to... The Top 10 Contract Research Organizations Key Findings The global CRO industry valued $18bn in 2008, an increase of 14% over 2007. The CRO market will grow at an annual rate of 14% over the 2009 13 period. Quintiles leads the global CRO market

More information

Product Lifecycle Management Through Patents

Product Lifecycle Management Through Patents Product Lifecycle Management Through Patents Strategic planning is not just for bit pharma anymore. Specialty pharma, drug delivery, biotech and even generic companies can all greatly benefit from careful

More information

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE

Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety

More information

St. George s University

St. George s University St. George s University 34-Credit MBA in Multi-Sector Health Management Course Description MGMT 900 Professional Practice: Most individuals in this program will not have an undergraduate business degree.

More information

Health Care Viewpoint

Health Care Viewpoint Global Penetration: Growth and Competitive Advantage Health Care Viewpoint Number 6 Bain health care expertise As the year 2000 approaches, the health care industry is still turbulent. Customer requirements

More information

Objectives of Presentation. Licensing in Biotech: A Business Development View. Definition of Biotech. The Biotech Window

Objectives of Presentation. Licensing in Biotech: A Business Development View. Definition of Biotech. The Biotech Window Licensing in Biotech: A Business Development View Objectives of Presentation Identify the dynamic forces inside a biotech company that influence license negotiation process Bus. 771 Simon Fraser University

More information

New Deals Are Moving from Scale to Strategic Value

New Deals Are Moving from Scale to Strategic Value Companies historically have viewed mergers and acquisitions as a way to spur growth by bulking up : adding scale and market share by combining with another organization offering similar or complementary

More information

Recent Global Trends and Opportunities in Pharmaceutical Business. Doğan FIDAN, MD, PhD, MBA

Recent Global Trends and Opportunities in Pharmaceutical Business. Doğan FIDAN, MD, PhD, MBA Recent Global Trends and Opportunities in Pharmaceutical Business Doğan FIDAN, MD, PhD, MBA Conference Centre Swissotel Krasnye Holmy Moscow, 3 March 2015 Outline Review of the global trends that affect

More information

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet Dalvir Gill, PhD - Chief Executive Officer 17 October, 2014 Presentation Objectives + TransCelerate History + Participating

More information

MedTech Outsourcing: Is the Past Any Indication of the Future?

MedTech Outsourcing: Is the Past Any Indication of the Future? MedTech Outsourcing: Is the Past Any Indication of the Future? Timothy Blair, Director, Global Business Development, NAMSA Strategic Perspective NAMSA Whitepaper #11 10/2014 MedTech Outsourcing: Is the

More information

Institute for OneWorld Health

Institute for OneWorld Health Institute for OneWorld Health a nonprofit pharmaceutical company Oxymoron no more: nonprofits can deliver medicines for the poor of the world January 10, 2005 Victoria Hale, PhD CEO, OneWorld Health The

More information

Rutgers Mini-MBA : BioPharma Innovation

Rutgers Mini-MBA : BioPharma Innovation Rutgers Mini-MBA : BioPharma Innovation Ga i n t h e s k i l l s to t r a n s f o r m scientific i n n ovat i o n i n to business success www.cmd.rutgers.edu/innovation Rutgers Mini-MBA : BioPharma Innovation

More information

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Brilliance in photodynamic technology TM Photocure ASA Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Agreement with Salix

More information

Unlock Your Global Business Potential: Supporting Life Sciences in the UK

Unlock Your Global Business Potential: Supporting Life Sciences in the UK Unlock Your Global Business Potential: Supporting Life Sciences in the UK Dr Mark Treherne, Chief Executive, Life Science Investment Organisation Health Research Authority 31 st March, 2014 THE UK HAS

More information

Debt Financing for Healthcare Companies: The Current State of the Market

Debt Financing for Healthcare Companies: The Current State of the Market Debt Financing for Healthcare Companies: The Current State of the Market Note: For the purposes of this paper, we will define healthcare as life sciences/biotech, medical devices, diagnostics and health

More information

CEO Interview Isao Moriyasu, President and CEO

CEO Interview Isao Moriyasu, President and CEO CEO Interview Isao Moriyasu, President and CEO June 2015 1. Fiscal 2014 Results Q: Looking back on fiscal 2014, the year ended March 31, 2015, could you discuss the results achieved as well as the progress

More information

The Procurement Value. and the key challenges to efficient execution

The Procurement Value. and the key challenges to efficient execution The Procurement Value IN LIFE SCIENCE and the key challenges to efficient execution Table of Contents Executive summary 3 1 Procurement: Untapped value for Pharmaceutical companies 4 2 Three main challenges

More information

2015 Russian Nanotechnology Investment Enabling Technology Leadership Award

2015 Russian Nanotechnology Investment Enabling Technology Leadership Award 2015 Russian Nanotechnology Investment Enabling Technology Leadership Award 2015 Contents Background and Company Performance... 3 Technology Leverage and Customer Impact of OJSC RUSNANO... 3-5 Conclusion...

More information

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q 2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements

More information

Open Innovation and Intellectual Property Rights The Two-edged Sword 1

Open Innovation and Intellectual Property Rights The Two-edged Sword 1 Open Innovation and Intellectual Property Rights The Two-edged Sword 1 Bronwyn H. Hall 2 A paradox? Open innovation implies an innovation ecosystem where ideas and knowledge flow across firm boundaries.

More information

Materials Management Overview

Materials Management Overview Partners HealthCare Overview Materials Management Overview Procurement Activity ACA Impact on Procurement 2 3 PARTNERS HEALTHCARE OVERVIEW Partners HealthCare System Incorporated was founded in 1994 by

More information

President and CEO. Research Park Corporation. Baton Rouge, Louisiana

President and CEO. Research Park Corporation. Baton Rouge, Louisiana July 2014 President and CEO Research Park Corporation Baton Rouge, Louisiana Introduction The Research Park Corporation (RPC) was established as a public, nonprofit corporation in 1992 by the Louisiana

More information

The Cybersecurity Research Alliance

The Cybersecurity Research Alliance The Cybersecurity Research Alliance Executive Summary Motivation is a national priority that must be addressed to defend our society economy from attacks that undermine their digital foundation. A coherent

More information

McKesson Corporation J.P. Morgan Healthcare Conference

McKesson Corporation J.P. Morgan Healthcare Conference McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer January 13, 2015 Forward-Looking Statements Some of the information in this presentation is not

More information

Rohan Shah, Yury Gloumakov, Yury Shprygov & Sabina Shukyurova

Rohan Shah, Yury Gloumakov, Yury Shprygov & Sabina Shukyurova Rohan Shah, Yury Gloumakov, Yury Shprygov & Sabina Shukyurova OUTLINE Overview of Russian Pharma Financing through FDI Cluster Theory and Application Policy Recommendations OVERVIEW OF RUSSIAN PHARMA Size

More information

BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD

BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD PARTNERING Trend Allows Smart CROs TO Provide Gamut of Services TO Any Size COMPANy Five years ago, contract research organizations

More information

Product Life Cycle Management in Life Sciences Industry

Product Life Cycle Management in Life Sciences Industry Life Cycle Management in Life Sciences Industry Evolving from siloed to cross-functional management Audit. Tax. Consulting. Corporate Finance. A need for Lifecycle Management Life Sciences companies are

More information

Investors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM 2015. Alliance. Innovation PRELIMINARY. Management

Investors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM 2015. Alliance. Innovation PRELIMINARY. Management OCTOBER 5-6, 2015 PARIS, FRANCE 6 th EDITION THE LEADING PARTNERING MEETING IN OPEN INNOVATION FOR LIFE SCIENCES CONFERENCES EXHIBITION HALL ONE-ON-ONE PARTNERING MEETINGS NETWORKING Open PRELIMINARY PROGRAM

More information

Pharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells

Pharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells Pharmaceutical Report Royalty Purchasing Industry Thomas R. Wells Table of Contents Industry Overview 2 How Transactions Work 2 Advantages & Disadvantages for Inventors and Investors 4 Major Investors

More information

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015 Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights October 27, 2015 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This presentation of Merck & Co., Inc.,

More information

What the Public Sector Should Know about Venture Capital

What the Public Sector Should Know about Venture Capital What the Public Sector Should Know about Venture Capital Roger Wyse, Managing Director and General Partner, Burrill & Company, U.S.A. ABSTRACT Ready access to venture capital investments is vital to the

More information

2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY

2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY 2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY AUGUST 2015 2 CMR FACTBOOK 2015 EXECUTIVE SUMMARY INTRODUCTION R&D productivity across the global biopharmaceutical industry is a well-documented

More information

Connect Digital Education And Work September, 2015

Connect Digital Education And Work September, 2015 Connect Digital Education And Work September, 2015 Interview with Kay Krafft, CEO Bertelsmann Education Two years ago Kay Krafft would never have dreamed that he would one day find himself in a hospital

More information

New Business Incubation

New Business Incubation New Business Incubation Jelto Smits CEO Technology Incubator Lighting and Innovation Analysts Day September 28, 2007 Disruptive Innovations Offer Greatest Returns Disruptive innovations do not start in

More information

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge

More information

GAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts

GAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering

More information

shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success

shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success Proven success and contacts. Not just talk. TCG is a

More information

End to End Development. Tackling the Challenges of Today s Pharmaceutical Industry

End to End Development. Tackling the Challenges of Today s Pharmaceutical Industry End to End Development Tackling the Challenges of Today s Pharmaceutical Industry John Curran Global CMC Regulatory Affairs Merck Manufacturing Division Oct 2011 1 Scope of Presentation Development Challenges

More information

Tech Launch Arizona. Start-up Guide For New Companies Licensing Technologies Invented at the University of Arizona

Tech Launch Arizona. Start-up Guide For New Companies Licensing Technologies Invented at the University of Arizona Tech Launch Arizona Start-up Guide For New Companies Licensing Technologies Invented at the University of Arizona Contents The Idea-to-Impact Continuum... 1 The TLA Start-up Pathway... 3 1. Investigator:

More information

Richard T. Clark Chief Executive Officer and President. Executing on Our Strategy

Richard T. Clark Chief Executive Officer and President. Executing on Our Strategy Richard T. Clark Chief Executive Officer and President Executing on Our Strategy Merck s Plan to Win: Preparing for Our Future Success BECOME THE MOST TRUSTED INDUSTRY LEADER IN DELIVERING VALUE TO CUSTOMERS

More information

THE WHAT AND WHY OF REGULATORY OUTSOURCING

THE WHAT AND WHY OF REGULATORY OUTSOURCING WHITE PAPER THE WHAT AND WHY OF REGULATORY OUTSOURCING Today s evolving healthcare landscape poses unprecedented challenges to biopharmaceutical companies. Consolidation, budget cuts, restructuring, globalization

More information

IDC MarketScape Excerpt: Worldwide Life Science R&D Strategic Consulting Services 2014 Vendor Assessment

IDC MarketScape Excerpt: Worldwide Life Science R&D Strategic Consulting Services 2014 Vendor Assessment IDC MarketScape IDC MarketScape Excerpt: Worldwide Life Science R&D Strategic Consulting Services 2014 Vendor Assessment Alan S. Louie, Ph.D. THIS IDC MARKETSCAPE EXCERPT FEATURES: ACCENTURE IDC MARKETSCAPE

More information

Kelley Executive Certificate in the Business of Life Sciences Is this your year to move ahead?

Kelley Executive Certificate in the Business of Life Sciences Is this your year to move ahead? Kelley Executive Certificate in the Business of Life Sciences Is this your year to move ahead? TAILORED TO THE INDUSTRY FLEXIBLE BUT CONSISTENT UNIQUE DELIVERY CROSS INDUSTRY NETWORKING THE ECBLS MEANS

More information

TIGroup Shareholder Update: Fiscal 2008 Major Goals Met or Exceeded. Revenue Run Rate Reaches $40M. Positive 2009 Outlook

TIGroup Shareholder Update: Fiscal 2008 Major Goals Met or Exceeded. Revenue Run Rate Reaches $40M. Positive 2009 Outlook News Release: FOR IMMEDIATE RELEASE TIGroup Shareholder Update: Fiscal 2008 Major Goals Met or Exceeded. Revenue Run Rate Reaches $40M. Positive 2009 Outlook BEVERLY HILLS, Calif. January 13, 2009 -- Tri-Isthmus

More information

IP throughout the life cycle of Xencor a biotech company

IP throughout the life cycle of Xencor a biotech company IP throughout the life cycle of Xencor a biotech company Bassil Dahiyat Ph.D. President and CEO Proteins by Design Xencor snapshot Biopharmaceutical company with proprietary platform technologies 21 US

More information

AN APPLICATION-CENTRIC APPROACH TO DATA CENTER MIGRATION

AN APPLICATION-CENTRIC APPROACH TO DATA CENTER MIGRATION AN APPLICATION-CENTRIC APPROACH TO DATA CENTER MIGRATION Five key success factors Whether the decision to relocate or consolidate a data center is driven by cost pressure or the need for greater IT efficiency,

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT. EXECUTIVE SUMMARY April 2013

CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT. EXECUTIVE SUMMARY April 2013 CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT EXECUTIVE SUMMARY April 2013 Copyright CMO Council. All Rights Reserved. 2013 ABSTRACT Change and transformation have become common occurrences if not required

More information

Goizueta Healthcare Forum 2011 Leadership in Healthcare Forum February 10 th - 11 th, 2011

Goizueta Healthcare Forum 2011 Leadership in Healthcare Forum February 10 th - 11 th, 2011 Goizueta Healthcare Forum 2011 Leadership in Healthcare Forum February 10 th - 11 th, 2011 Schedule of Events February 10 th 6:30-7:15pm: Opening Address: Scott Lloyd, Co-Founder and President of Extrakare,

More information

Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute

Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information

More information

Biotech funding surges

Biotech funding surges www.pwc.com Biotech funding surges Biotechnology investments in the fourth quarter of 2014 reached the highest level recorded since the MoneyTree TM data series was launched in 1995, breaking a record

More information

Outsourcing in a Changing Environment

Outsourcing in a Changing Environment Outsourcing in a Changing Environment Commercial Solutions from Quintiles Copyright 2013 Quintiles Objectives Discuss the evolution of outsourcing Do cost efficiencies, i i flexibility and productivity

More information

Innovations in Drug Delivery

Innovations in Drug Delivery Innovations in Drug Delivery Arthur J. Tipton, Ph.D. March 13, 2012 UAB CAS From APIs to drug delivery solutions Exclusive Synthesis Proprietary advanced intermediates and APIs, from the clinical stage

More information

Closed innovation vs. open innovation 2 What is open innovation, and how does it differ from previous models, like the closed innovation systems?

Closed innovation vs. open innovation 2 What is open innovation, and how does it differ from previous models, like the closed innovation systems? Open Innovation Basics and the Local Environment Introduction Micro-, Small- and Medium-Enterprises are global drivers of innovation and business development depending on the knowledge-base as a key resource.

More information

The majority of pharmaceutical companies in

The majority of pharmaceutical companies in Pharmaceutical Infrastructure and Industry Professor Che-Ming Teng, Ph.D. National Taiwan University College of Medicine, Taipei, Taiwan The majority of pharmaceutical companies in Taiwan are devoted to

More information

Procurement must be more than just cost cutting

Procurement must be more than just cost cutting Procurement must be more than just cost cutting In today s challenging environment, aggressive cost control has become a common theme in the pharmaceutical industry. It became fashionable later than in

More information

Product Lifecycle Management in the Food and Beverage Industry. An Oracle White Paper Updated February 2008

Product Lifecycle Management in the Food and Beverage Industry. An Oracle White Paper Updated February 2008 Product Lifecycle Management in the Food and Beverage Industry An Oracle White Paper Updated February 2008 Product Lifecycle Management in the Food and Beverage Industry EXECUTIVE OVERVIEW Companies in

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

Our strategy Setting the course

Our strategy Setting the course Our strategy Our strategy Setting the course 46 Our strategy Strategy sets the course To leverage the diverse opportunities of our complex world, a company needs a clear direction, a strong internal setup,

More information

The 505(b)(2) Drug Development Pathway:

The 505(b)(2) Drug Development Pathway: The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive

More information

Department for Business, Innovation and Skills: Science and Innovation Strategy 2014 Response from Alzheimer s Research UK

Department for Business, Innovation and Skills: Science and Innovation Strategy 2014 Response from Alzheimer s Research UK Department for Business, Innovation and Skills: Science and Innovation Strategy 2014 Response from Alzheimer s Research UK 1. Introduction 1.1. Alzheimer s Research UK is the UK s leading dementia research

More information

Best Practices for Launching Tech Ventures and Leveraging the University Mission Accelerating New Ventures

Best Practices for Launching Tech Ventures and Leveraging the University Mission Accelerating New Ventures Best Practices for Launching Tech Ventures and Leveraging the University Mission Accelerating New Ventures 2011 The University of Texas at Austin IC2 Institute 1 Overview Review of Traditional Innovation

More information

Specialty Logistics Outlook. Six facts to focus on in the coming year.

Specialty Logistics Outlook. Six facts to focus on in the coming year. 2015 Specialty Logistics Outlook Six facts to focus on in the coming year. THE BRIC NATIONS BRAZIL, RUSSIA, INDIA AND CHINA ARE POSITIONED TO ACCOUNT FOR MORE THAN $248 BILLION IN PHARMACEUTICAL SALES

More information

The European Perspective

The European Perspective Back on Track Back on Track The European Perspective E UROPEAN INTRODUCTION Back on Track Europe s biotech industry is decisively back on track. After years of consolidation and relatively stagnant results,

More information

Digital Customer Experience

Digital Customer Experience Digital Customer Experience Digital. Two steps ahead Digital. Two steps ahead Organizations are challenged to deliver a digital promise to their customers. The move to digital is led by customers who are

More information

HINJ and New Jersey s Life Sciences Community

HINJ and New Jersey s Life Sciences Community HINJ and New Jersey s Life Sciences Community Since 1997, the HealthCare Institute of New Jersey (HINJ) has ser ved as the leading voice of the state s life sciences industr y. HINJ seeks to expand patient

More information

September 29, About BIO

September 29, About BIO The Comments of the Biotechnology Industry Organization on the Discussion Paper on Compulsory Licenses Published by the Department of Industrial Policy and Promotion within India's Ministry of Commerce

More information

Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine

Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine Martin LeBlanc, President and CEO, Caprion The 2014 ISPIM Americas Innovation Forum October 6, 2014 1 CHALLENGES FOR

More information

Eudendron: an Innovative Biotech Start-up

Eudendron: an Innovative Biotech Start-up Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description

More information

In the largest and perhaps the most ambitious collaborative

In the largest and perhaps the most ambitious collaborative FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

More information

The Healthcare market in Brazil

The Healthcare market in Brazil www.pwc.com.br The Healthcare market in Brazil Brazilian Healthcare market: one of the most promising and attractive in the world Context Fifth largest country in area and population, with 8.51 million

More information

Pharma Industry, The Next Challenge Improving Clinical and Economic Value

Pharma Industry, The Next Challenge Improving Clinical and Economic Value Pharma Industry, The Next Challenge Improving Clinical and Economic Value BY ASHLEY WOOLMORE, MIKE STANDING AND JAMES WELLS A new economic framework for end-to-end management for pharmaceutical companies

More information

White Paper 4 Indication Sequencing for a New Molecular Entity with Multiple Potential Indications

White Paper 4 Indication Sequencing for a New Molecular Entity with Multiple Potential Indications White Paper 4 ation Sequencing for a New Molecular Entity with Multiple Potential ations Jack Kloeber, Jr. PhD, C. Kwon Kim PhD, and Alex Stojanovic PhD KROMITE, LLC Every pharmaceutical or biotechnology

More information

Global Headquarters: 5 Speen Street Framingham, MA 01701 USA P.508.872.8200 F.508.935.4015 www.idc.com

Global Headquarters: 5 Speen Street Framingham, MA 01701 USA P.508.872.8200 F.508.935.4015 www.idc.com WHITE PAPER Network Consulting Services Lead Enterprise Transformation Sponsored by: HP Leslie Rosenberg February 2011 Curtis Price Global Headquarters: 5 Speen Street Framingham, MA 01701 USA P.508.872.8200

More information

Creative financing: Private equity in life sciences

Creative financing: Private equity in life sciences : Private equity in life sciences The Colonnade Hotel, Boston, MA October 28, 2008 Industry trends and implications 2 Setting the Stage Overall trends Aging population Emerging market opportunities - access

More information

BioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover

BioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover The rocky way from science to market Dr. Karsten Fischer BioMedPartners AG VPM Days Hannover November 2013 Content I. Stage 1 II. Setbacks 6 III. Hope 12 IV. Solutions 17 V. Expertise 20 Page 1 The Challenge

More information

Keys To IP Collaborations With Universities: Part 3

Keys To IP Collaborations With Universities: Part 3 Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Keys To IP Collaborations With Universities: Part

More information

Acucela Inc. IR Meeting

Acucela Inc. IR Meeting Acucela Inc. IR Meeting Tokyo May 20, 2015 Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening

More information

Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato

Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato Ennio Ongini Nicox Consiglio Nazionale delle Ricerche Quarta Giornata Informativa "Dalla ricerca al Trasferimento

More information

From Data to Foresight:

From Data to Foresight: Laura Haas, IBM Fellow IBM Research - Almaden From Data to Foresight: Leveraging Data and Analytics for Materials Research 1 2011 IBM Corporation The road from data to foresight is long? Consumer Reports

More information

B8746: Investing in Medical Technologies Fall 2015 (B-Term); Monday 5:45pm 9:00pm

B8746: Investing in Medical Technologies Fall 2015 (B-Term); Monday 5:45pm 9:00pm B8746: Investing in Medical Technologies Fall 2015 (B-Term); Monday 5:45pm 9:00pm Instructor: Office: Email: TA: Email: Efrem Kamen, Founder & Managing Member, Pura Vida Investments, LLC TBD ejk28@columbia.edu

More information

21ST CENTURY ELECTRICITY SYSTEM CEO FORUM SUMMARY

21ST CENTURY ELECTRICITY SYSTEM CEO FORUM SUMMARY ADVANCED ENERGY ECONOMY the business voice of advanced energy 21ST CENTURY ELECTRICITY SYSTEM CEO FORUM SUMMARY HOSTED BY MIT, CAMBRIDGE, MA On March 6th, Advanced Energy Economy (AEE) & MIT s Industrial

More information

Biomedical Business: Current Trends, Product Challenges and Future Outlook

Biomedical Business: Current Trends, Product Challenges and Future Outlook Biomedical Business: Current Trends, Product Challenges and Future Outlook Prepared and Presented by Audrey S. Erbes, Ph.D. Principal, Erbes & Associates Life Science Marketing and Business Development

More information

The Analytics COE: the key to Monetizing Big Data via Predictive Analytics

The Analytics COE: the key to Monetizing Big Data via Predictive Analytics www.hcltech.com The Analytics COE: the key to Monetizing Big Data via Predictive Analytics big data & business analytics AuthOr: Doug Freud Director, Data Science WHITEPAPER AUGUST 2014 In early 2012 Ann

More information